Enzymatic and virological data support the idea that naturally occurring polymorphisms in different non W sub-types can impact the susceptibility of HIV 1 to different antiretroviral Enzalutamide manufacturer drugs, the magnitude of resistance conferred by key mutations, and the propensity to obtain some resistance mutations. More over, in vitro studies suggested that subtype H integrase is equally prone to INSTIs. Similarly, the evaluation of pol gene in infected patients showed that extremely commonplace polymorphisms have little influence on INSTIs susceptibility. Nonetheless, the contrast of IN sequences of B and CRF02 AG traces showed that CRF02 AG sequence differs fromthe B sequence by 13 residues. Based on a type of the B HIV 1 integrase/DNA complex, it was suggested that a number of these variations K/R14, T/V112, T/A125, G/N134, K/T136, and T/S206 might impact IN interaction with skeletal systems DNA or IN susceptibility to INSTIs. Later we compared the genetic boundaries between T and CRF02 AG traces, we found that the variability between sub-types impacted the genetic barrier for G140C/S and V151I using a higher genetic barrier being determined for subtype CRF02 AG suggesting a great difficulty in selecting these mutations for CR02 AG compared to subtype B. Integrase is just a 288 proteins chemical, which consists in three structurally distinct functional domains. Buildings reporting HIV 1 IN single or two area data allow the generation of biologically related types, representing both unbound dimeric enzyme or IN complexes with viral and/or host DNA. The X-ray components of full-length model foamy disease buy Bicalutamide IN complex with its cognate DNA and integrase string move inhibitors were recently resolved. The reported buildings were employed for homology modeling of the unbound IN and IN destined to vDNA from CRF02 AG and B strains. More, the created types were used to estimate the susceptibility of both INs to strand transfer inhibitors, RAL, ELV and L731,988. Effects from molecular modeling were in comparison to experimental data obtained with B and CRF02 AG INs which were separated from plasma samples of HIV 1 infected individuals and then cloned and expressed in vitro. The complete sequence of the IN coding region of the pol gene was amplified and cloned in the plasma samples of CRF02 AG HIV 1 infected patients. Four IN sequences, N1 to N4, harbored many variations one of the thirteen residues which were proved to be put through polymorphic substitutions between CRF02 AG and T HIV 1 sequences. The patient from whom the IN coding DNA was derived was not subjected to the INSTI containing therapy, even though Q148K is involved in INSTIs resistance. Therefore we assume that Q148K might be a naturally occurring amino acid substitution.